Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

692
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
692
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

478
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
478
Censoring Survival Data01:09

Censoring Survival Data

629
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
629
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

695
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
695
Actuarial Approach01:20

Actuarial Approach

356
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
356
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

924
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
924

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medial Unicompartmental Versus Total Knee Arthroplasty in the Treatment of Isolated Anteromedial Knee Osteoarthritis: Two-Year Results from a Double-Blinded, Multicenter, Randomized Trial of 350 Patients.

The Journal of bone and joint surgery. American volume·2026
Same author

Empirical Likelihood Comparison of Absolute Risks.

Biometrical journal. Biometrische Zeitschrift·2025
Same author

Correction to "Propensity weighting plus adjustment in proportional hazards model is not doubly robust," by Erin E. Gabriel, Michael C. Sachs, Ingeborg Waernbaum, Els Goetghebeur, Paul F. Blanche, Stijn Vansteelandt, Arvid Sjölander, and Thomas Scheike; Volume 80, Issue 3, September 2024, https://doi.org/10.1093/biomtc/ujae069.

Biometrics·2025
Same author

Sample size recalculation in three-stage clinical trials and its evaluation.

BMC medical research methodology·2024
Same author

Sample Size Calculation Under Nonproportional Hazards Using Average Hazard Ratios.

Biometrical journal. Biometrische Zeitschrift·2024
Same author

Propensity weighting plus adjustment in proportional hazards model is not doubly robust.

Biometrics·2024
Same journal

A Causal Framework for Evaluating the Total Effect of Strategies Aiming to Expand Screening and to Improve Outcomes.

Statistics in medicine·2026
Same journal

Causal Effects on Nonterminal Event Time With Application to Antibiotic Usage and Future Resistance.

Statistics in medicine·2026
Same journal

Subgroup Analysis of Interval-censored Failure Time Data With Application to Alzheimer's Disease.

Statistics in medicine·2026
Same journal

Rejoinder to Commentaries on "A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events".

Statistics in medicine·2026
Same journal

A Multi-Stage Drop-the-Loser Design With Superiority Boundaries.

Statistics in medicine·2026
Same journal

Interpretable ROI Identification in Brain Image Analysis: Overcoming CNN Black Box Challenges With Kriging-Enhanced Adaptive Sampling.

Statistics in medicine·2026
See all related articles

Related Experiment Video

Updated: Mar 20, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K

Sample Size Recalculation in Adaptive Group Sequential Study Designs for Comparing Restricted Mean Survival Times.

Carolin Herrmann1,2, Paul Blanche3

  • 1Mathematical Institute, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Statistics in Medicine
|March 18, 2026
PubMed
Summary
This summary is machine-generated.

Adaptive clinical trial designs using restricted mean survival time (RMST) are crucial for handling non-proportional hazards. This study explains adaptive designs with RMST, offering a robust method for sample size adaptation in trials with delayed treatment effects.

Keywords:
adaptive clinical trialdelayed treatment effectnon‐proportional hazardsrestricted mean survival timesample size adaptationtime‐to‐event analysis

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K

Related Experiment Videos

Last Updated: Mar 20, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Survival Analysis

Background:

  • Non-proportional hazards are common in time-to-event clinical trials, making hazard ratios potentially misleading.
  • Restricted Mean Survival Time (RMST) is an increasingly promoted alternative endpoint for treatment effect comparison.
  • Sample size calculation for RMST trials requires precise nuisance parameter estimates, posing planning challenges.

Purpose of the Study:

  • To evaluate adaptive group sequential designs for clinical trials comparing RMST, particularly with delayed treatment effects.
  • To compare the performance of adaptive RMST designs against other common endpoints in scenarios with delayed treatment effects.
  • To provide a thorough explanation and methodology for adaptive RMST designs.

Main Methods:

  • Extensive simulation study comparing adaptive designs with RMST as the primary endpoint.
  • Focus on sample size adaptations within adaptive group sequential designs.
  • Development and evaluation of a combination test applicable to various adaptations.

Main Results:

  • Adaptive designs with RMST demonstrate robust performance in handling non-proportional hazards and delayed treatment effects.
  • The proposed adaptive RMST design offers a viable solution to sample size uncertainties in trial planning.
  • The combination test shows utility beyond sample size adaptations.

Conclusions:

  • Adaptive group sequential designs utilizing RMST are effective for clinical trials with non-proportional hazards and delayed treatment effects.
  • The methodology presented enhances the reliability and power of clinical trials by allowing sample size adaptations.
  • The developed combination test offers flexibility for various adaptive trial strategies.